Loading…
Based on limited metadata with no full letter text available, CGA Limited, a drug manufacturer, received an FDA Warning Letter on December 19, 2019, indicating regulatory compliance issues with their pharmaceutical products. While the specific violations are not detailed in the available metadata, the warning falls under FDA drug regulation and enforcement. Without access to the complete letter contents or issuing office details, the precise nature and scope of the violations cannot be definitively characterized, though the warning suggests significant deficiencies requiring corrective action by the company.